Vol 52(2018) N 4 p. 629-635; DOI 10.1134/S0026893318040155
V.D. Pivovarov1, D.Yu. Ryazantsev1, M.A. Simonova1, T.V. Yegorova1 , S.V. Khlgatian2, S.K. Zavriev1, E.V. Svirshchevskaya1*
Immuno-PCR Assay for Quantitation of Antibodies to Epstein-Barr Virus1Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997 Russia
2Mechnikov Institute of Vaccines and Sera, Moscow, 105064 Russia
Received - 2017-11-09; Accepted - 2017-12-12
Successful disease prevention and therapy critically depend on timely diagnosis of infections. Quantitative immuno-PCR (qiPCR) technology improves the sensitivity in the detection of antibodies to pathogens. A qiPCR-based assay was developed to determine IgG antibodies to Epstein-Barr virus (EBV) in the human blood serum. EBV nuclear protein 1 fragment (pEBV) was expressed in Escherichia coli. A synthetic single-stranded deoxyribonucleotide was conjugated to streptavidin, and the conjugate was used to detect рEBV-IgG1-biotin complexes by qiPCR. The IgG1 titers determined by qiPCR were compared to the results of enzyme-linked immunosorbent assay (ELISA). The sensitivity of qiPCR was one order of magnitude higher than that of ELISA. Thus, a highly sensitive qiPCR-based assay was developed to quantitate antibodies specific to the recombinant EBV antigen.
quantitative immuno-PCR, ELISA, recombinant proteins, Epstein-Barr virus, EBNA1, IgG1